I. Hillebrand
- Endocrinology, Diabetes and Metabolism top 10%
- Molecular Biology
- Nutrition and Dietetics
- Pharmacology
- Physiology
- Topics
- Natural Antidiabetic Agents Studies (11 papers)Diabetes Treatment and Management (10 papers)Pharmacology and Obesity Treatment (7 papers)
- Partner nations
- GermanyGreeceUnited Kingdom
In The Last Decade
I. Hillebrand
19 papers receiving 268 citations
Peers
Comparison fields: 5 of 52
- Endocrinology, Diabetes and Metabolism 192
- Molecular Biology 83
- Nutrition and Dietetics 66
- Pharmacology 63
- Physiology 54
Countries citing papers authored by I. Hillebrand
This map shows the geographic impact of I. Hillebrand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Hillebrand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Hillebrand more than expected).
Fields of papers citing papers by I. Hillebrand
This network shows the impact of papers produced by I. Hillebrand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Hillebrand. The network helps show where I. Hillebrand may publish in the future.
Co-authorship network of co-authors of I. Hillebrand
This figure shows the co-authorship network connecting the top 25 collaborators of I. Hillebrand. A scholar is included among the top collaborators of I. Hillebrand based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I. Hillebrand. I. Hillebrand is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 5 | |
| 3 | 16 | |
| 4 | 10 | |
| 5 | 3 | |
| 6 | 1 | |
| 7 | 1 | |
| 8 | 6 | |
| 9 | 5 | |
| 10 | The clinical efficacy of a second-generation alpha-glucosidase inhibitor in non-insulin-dependent diabetic patients. | 2 |
| 11 | Assessment of the clinical efficacy and tolerance of two new alpha-glucosidase inhibitors in insulin-treated diabetics. | 1 |
| 12 | A double-blind study on the efficacy and tolerance of a new alpha-glucosidase inhibitor in type-2 diabetics. | 20 |
| 13 | 18 | |
| 14 | 23 | |
| 15 | 11 | |
| 16 | Long-term effect of acarbose on diurnal serum triglyceride, glucose, insulin and adipose tissue lipoprotein lipase levels in patients with primary endogenous hypertriglyceridaemia, with or without type II diabetes. | 4 |
| 17 | 21 | |
| 18 | 5 | |
| 19 | 90 | |
| 20 | 51 |
About I. Hillebrand
I. Hillebrand is a scholar working on Endocrinology, Diabetes and Metabolism, Pharmacology and Biotechnology, having authored 20 papers that have together received 293 indexed citations. Recurring topics across this work include Natural Antidiabetic Agents Studies (11 papers), Diabetes Treatment and Management (10 papers) and Pharmacology and Obesity Treatment (7 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (192 citations), Nutrition and Dietetics (66 citations) and Pharmacology (63 citations). I. Hillebrand has collaborated with scholars based in Germany, Greece and United Kingdom. Frequent co-authors include K. Boehme, Peter Berchtold, H. Fink, K.‐H. Graefe, Luc Tappy, E Temler, J. Pichl, Michel Cauderay, Wolfram Domschke and Jean‐Pierre Felber. Their work appears in journals such as Gastroenterology, Metabolism and Diabetic Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.